Journal of Cancer Research and Therapeutics

ORIGINAL ARTICLE
Year
: 2020  |  Volume : 16  |  Issue : 2  |  Page : 372--378

Feasibility and clinical value of computed tomography-guided125I brachytherapy for pain palliation in patients with retroperitoneal lymph node metastases


Qicong Mai1, Zhiqiang Mo2, Jian He2, Meng Chen2, Qing Gou2, Feng Shi2, Xiaoming Chen1 
1 Department of Interventional Oncology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China
2 Department of Interventional Oncology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China

Correspondence Address:
Xiaoming Chen
Department of Interventional Oncology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences; The Second School of Clinical Medicine, Southern Medical University, Guangzhou
China

Aims: The aim was to evaluate the feasibility and clinical value of computed tomography (CT)-guided125 I brachytherapy for pain palliation in patients with retroperitoneal lymph node metastases. Materials and Methods: A total of 23 patients with retroperitoneal lymph node metastases and those who had moderate-to-severe pain from January 2014 to December 2018 were enrolled in the study. The primary tumors included pancreatic (n = 12), gastric (n = 4), hepatocellular (n = 4), colorectal (n = 2), and esophageal carcinomas (n= 1). Patients were treated with CT-guided percutaneous125 I brachytherapy during the study. The Brief Pain Inventory-Short Form was used to record and compare pain intensity and interference by pain. Treatment-related complications were also evaluated according to the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer Late Radiation Morbidity Scoring Criteria. Statistical analysis was performed using SPSS software version 22.0 Results: The primary success rate of125 I seed implantation was 95.7% (22 of the 23 patients). As pain evolved, the patients achieved obvious pain palliation ratings for “worst pain” and “average pain” at 72 h and 4 weeks after brachytherapy, respectively, whereas “pain right now” at 12 weeks was significantly relieved after brachytherapy. No serious complications developed during the perioperative period. Conclusions: In the treatment of intractable carcinomatous pain in patients with retroperitoneal lymph node metastases, CT-guided125 I brachytherapy is a feasible and effective modality for pain palliation.


How to cite this article:
Mai Q, Mo Z, He J, Chen M, Gou Q, Shi F, Chen X. Feasibility and clinical value of computed tomography-guided125I brachytherapy for pain palliation in patients with retroperitoneal lymph node metastases.J Can Res Ther 2020;16:372-378


How to cite this URL:
Mai Q, Mo Z, He J, Chen M, Gou Q, Shi F, Chen X. Feasibility and clinical value of computed tomography-guided125I brachytherapy for pain palliation in patients with retroperitoneal lymph node metastases. J Can Res Ther [serial online] 2020 [cited 2021 Oct 21 ];16:372-378
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2020;volume=16;issue=2;spage=372;epage=378;aulast=Mai;type=0